Health-focussed SaaS startup Zealthix raises $1.1 M in seed round led by Unicorn India Ventures

IMT News Desk
IMT News Desk
· 3 min read

Funds raised to be used for expansion and revenue growth

Zealthix, a comprehensive SaaS based Healthcare platform, has raised $1.1 million in a seed round led by Unicorn India Ventures with participation from AlphaGen Venture Capital.

Funds raised will be used for expansion and revenue growth. Additionally, a sizable portion will also be invested in making technology more robust and achieving the mission of making the Indian Healthcare ecosystem more digitized, streamlined, and interoperable.

Anil Joshi, Managing Partner, Unicorn India Ventures, says, “Advances in cloud computing have massively changed the technological landscape of businesses. India’s healthcare SaaS sector has entered a golden phase of adoption, showing a promising ability to offer quality and timely services. What we are witnessing is not just digitisation but the creation of a robust, scalable healthcare ecosystem which will redefine how healthcare services are offered. The company has witnessed progress in the last 12 months and has designed new technology solutions. Hence, we believe the market opportunity is huge and the company has built the right momentum to capitalise on this segment.”

Zealthix has been certified by NHA as a connector, which can make any Health provider using proprietary technology become ABDM compliant and interoperable. It is the first platform to be certified by ONDC for Healthcare Seller Node. This will democratize the healthcare service distribution in India. Additionally, Zealthix’s ubiquitous provider platform is enabling Health Providers to become technology ready, leveraging the power of AI to manage their business seamlessly using partner management, contract management, payment & reconciliation, smarter customer engagement, compliance, data digitization, smart report, and more.

Abhishek Kumar, Co-founder and CEO, Zealthix, says, “Having built businesses, which created categories such as BeatO (first in Condition/Care/Disease Management space) & BookMyCab (first in cab aggregation space), we are driven by our passion for making the Indian Healthcare Ecosystem more digitised, streamlined and interoperable. Be it OPD or In-patient experience, as customers, we encounter broken systems, offline processes and poor experience. The government, too, is looking to digitise the healthcare ecosystem. Providers are looking to become more technology-efficient. The timing and support we are getting from the ecosystem is tremendous. We want to contribute in our own ways to help various stakeholders with technology, workflow, digitisation and AI adoption.’

Over the next 12 months, Zealthix aims to double down on reaching out to health providers, understanding their issues, helping them with technology to make their business more efficient, compliant, digitised and interoperable.

On the payer side, the company’s OPD stack will continue to evolve and will start catering to all possible use cases. With technology and a robust SaaS platform, it will empower payers to configure & launch health products very quickly and be able to deep dive on the product performance, including sales, utilisation and renewals using our pre-built customizable tools.

Read Next

India successfully validates the first indigenous HPV test for Cervical Cancer screening
News
June 13, 2026

India successfully validates the first indigenous HPV test for Cervical Cancer screening

India has achieved a significant milestone in cervical cancer prevention with the successful validation of the country’s first indigenous HPV DNA tests, which meet international standards for cervical cancer screening. Published in the International Journal of Cancer, a multicentre study involving leading Indian and international institutions found that Molbio Diagnostics Truenat HPV-HR Plus met the […]
Article by: IMT News Desk
Glenmark Launches Winlevi® in Key European Markets for the Treatment of Acne Vulgaris
News
June 12, 2026

Glenmark Launches Winlevi® in Key European Markets for the Treatment of Acne Vulgaris

Glenmark Specialty S.A. (GSSA), a wholly owned subsidiary of Glenmark Pharmaceuticals Ltd., has announced the launch of Winlevi® (clascoterone 10 mg/g cream) across key markets in Europe. This follows the grant of marketing authorization of the product for the treatment of acne vulgaris in both adults and adolescents aged 12 to <18 years (with usage in […]
Article by: IMT News Desk
Thyrocare Expands Its Presence in Prayagraj with the Launch of Its New Diagnostic Laboratory
News
June 12, 2026

Thyrocare Expands Its Presence in Prayagraj with the Launch of Its New Diagnostic Laboratory

Thyrocare Technologies Limited has announced the set-up of its new diagnostic laboratory in Prayagraj, Uttar Pradesh, in association with SecondMedic. The new laboratory is equipped with advanced testing infrastructure and supported by trained professionals, enabling timely and error-free diagnostic results. It caters to both specialised and routine testing requirements, offering support to ongoing and preventive […]
Article by: IMT News Desk
AstraZeneca Gets CDSCO Approval for Trastuzumab Deruxtecan in HER2-Positive Breast Cancer
News
June 12, 2026

AstraZeneca Gets CDSCO Approval for Trastuzumab Deruxtecan in HER2-Positive Breast Cancer

AstraZeneca Pharma India Ltd. (AZPIL) announced that the Central Drugs Standard Control Organisation (CDSCO) has approved an additional indication for Trastuzumab Deruxtecan 100 mg/5 mL vial lyophilized powder for concentrate for solution for infusion, in combination with Pertuzumab as a first-line treatment for adult patients with unresectable or metastatic HER2-positive (IHC 3+ or ISH+) breast cancer. In India, HER2-positive breast […]
Article by: IMT News Desk